Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOSTA: Regorafenib as Maintenance Therapy After First-line Treatment in Bone Sarcomas
NCT04055220Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in bone sarcoma, sponsored by Centre Léon Bérard. Started Mar 2020; status: recruiting.
02
Drugs
regorafenib
03
Conditions
bone sarcoma
Beyond the preview
Go deeper on NCT04055220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055220.